Minimization and withdrawal of steroids in pancreas and islet transplantation

Davide Mineo, Junichiro Sageshima, George W. Burke, Camillo Ricordi

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

For reducing the corticosteroid (CS)-related side-effects, especially cardiovascular events, CS-sparing protocols have become increasingly common in pancreas transplantation (PT). Lympho-depleting induction antibodies, such as rabbit anti-thymocyte globulin (rATG) or alemtuzumab, have been widely used in successful trials. The results of various CS-sparing protocols combining calcineurin inhibitors (CNI) and mycophenolate or sirolimus, have been mixed for rejection and survival rates. Most of the studies were uncontrolled trials of low-risk patients, therefore the grade of evidence is limited. Large-scale prospective studies with long-term follow up are necessary to assess risks and benefits of CS-sparing regimens in PT before recommending such strategies as standard practice. Islet allo-transplantation for patients with brittle type 1 diabetes mellitus, less invasive and safer procedure than PT, has been attempted since late 1980s, but diabetogenic immunosuppressants at maintenance, mainly CS and high-dose CNI, prevented satisfactory results (10% insulin-independence at 1-year post-transplant). Since 2000, CS-free and CNI-reducing protocols, including more potent induction [daclizumab, OKT3γ1(ala-ala) anti-CD3 antibody, rATG] and maintenance (sirolimus, mycophenolate) agents, have significantly improved short-term outcomes whereas long-term are still inadequate (from 80% to 20% insulin-independence from 1- to 5-year post-transplant). Main limitations are allo- and autoimmunity, immunosuppression-related islet and systemic toxicity and transplant site unsuitability, which tolerogenic protocols and biotechnological solutions may solve.

Original languageEnglish (US)
Pages (from-to)20-37
Number of pages18
JournalTransplant International
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Pancreas Transplantation
Islets of Langerhans Transplantation
Adrenal Cortex Hormones
Steroids
Antilymphocyte Serum
Sirolimus
Transplants
Type 1 Diabetes Mellitus
Maintenance
Insulin
Rabbits
Immunosuppressive Agents
Autoimmunity
Immunosuppression
Anti-Idiotypic Antibodies
Survival Rate
Prospective Studies
Antibodies
Calcineurin Inhibitors

Keywords

  • Gluco-corticosteroids
  • Immunosuppression
  • Islet transplantation
  • Pancreas transplantation
  • Side-effects
  • Toxicity

ASJC Scopus subject areas

  • Transplantation

Cite this

Minimization and withdrawal of steroids in pancreas and islet transplantation. / Mineo, Davide; Sageshima, Junichiro; Burke, George W.; Ricordi, Camillo.

In: Transplant International, Vol. 22, No. 1, 01.01.2009, p. 20-37.

Research output: Contribution to journalReview article

Mineo, Davide ; Sageshima, Junichiro ; Burke, George W. ; Ricordi, Camillo. / Minimization and withdrawal of steroids in pancreas and islet transplantation. In: Transplant International. 2009 ; Vol. 22, No. 1. pp. 20-37.
@article{7639b46d1bc643189cd90c30b2c88351,
title = "Minimization and withdrawal of steroids in pancreas and islet transplantation",
abstract = "For reducing the corticosteroid (CS)-related side-effects, especially cardiovascular events, CS-sparing protocols have become increasingly common in pancreas transplantation (PT). Lympho-depleting induction antibodies, such as rabbit anti-thymocyte globulin (rATG) or alemtuzumab, have been widely used in successful trials. The results of various CS-sparing protocols combining calcineurin inhibitors (CNI) and mycophenolate or sirolimus, have been mixed for rejection and survival rates. Most of the studies were uncontrolled trials of low-risk patients, therefore the grade of evidence is limited. Large-scale prospective studies with long-term follow up are necessary to assess risks and benefits of CS-sparing regimens in PT before recommending such strategies as standard practice. Islet allo-transplantation for patients with brittle type 1 diabetes mellitus, less invasive and safer procedure than PT, has been attempted since late 1980s, but diabetogenic immunosuppressants at maintenance, mainly CS and high-dose CNI, prevented satisfactory results (10{\%} insulin-independence at 1-year post-transplant). Since 2000, CS-free and CNI-reducing protocols, including more potent induction [daclizumab, OKT3γ1(ala-ala) anti-CD3 antibody, rATG] and maintenance (sirolimus, mycophenolate) agents, have significantly improved short-term outcomes whereas long-term are still inadequate (from 80{\%} to 20{\%} insulin-independence from 1- to 5-year post-transplant). Main limitations are allo- and autoimmunity, immunosuppression-related islet and systemic toxicity and transplant site unsuitability, which tolerogenic protocols and biotechnological solutions may solve.",
keywords = "Gluco-corticosteroids, Immunosuppression, Islet transplantation, Pancreas transplantation, Side-effects, Toxicity",
author = "Davide Mineo and Junichiro Sageshima and Burke, {George W.} and Camillo Ricordi",
year = "2009",
month = "1",
day = "1",
doi = "10.1111/j.1432-2277.2008.00761.x",
language = "English (US)",
volume = "22",
pages = "20--37",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Minimization and withdrawal of steroids in pancreas and islet transplantation

AU - Mineo, Davide

AU - Sageshima, Junichiro

AU - Burke, George W.

AU - Ricordi, Camillo

PY - 2009/1/1

Y1 - 2009/1/1

N2 - For reducing the corticosteroid (CS)-related side-effects, especially cardiovascular events, CS-sparing protocols have become increasingly common in pancreas transplantation (PT). Lympho-depleting induction antibodies, such as rabbit anti-thymocyte globulin (rATG) or alemtuzumab, have been widely used in successful trials. The results of various CS-sparing protocols combining calcineurin inhibitors (CNI) and mycophenolate or sirolimus, have been mixed for rejection and survival rates. Most of the studies were uncontrolled trials of low-risk patients, therefore the grade of evidence is limited. Large-scale prospective studies with long-term follow up are necessary to assess risks and benefits of CS-sparing regimens in PT before recommending such strategies as standard practice. Islet allo-transplantation for patients with brittle type 1 diabetes mellitus, less invasive and safer procedure than PT, has been attempted since late 1980s, but diabetogenic immunosuppressants at maintenance, mainly CS and high-dose CNI, prevented satisfactory results (10% insulin-independence at 1-year post-transplant). Since 2000, CS-free and CNI-reducing protocols, including more potent induction [daclizumab, OKT3γ1(ala-ala) anti-CD3 antibody, rATG] and maintenance (sirolimus, mycophenolate) agents, have significantly improved short-term outcomes whereas long-term are still inadequate (from 80% to 20% insulin-independence from 1- to 5-year post-transplant). Main limitations are allo- and autoimmunity, immunosuppression-related islet and systemic toxicity and transplant site unsuitability, which tolerogenic protocols and biotechnological solutions may solve.

AB - For reducing the corticosteroid (CS)-related side-effects, especially cardiovascular events, CS-sparing protocols have become increasingly common in pancreas transplantation (PT). Lympho-depleting induction antibodies, such as rabbit anti-thymocyte globulin (rATG) or alemtuzumab, have been widely used in successful trials. The results of various CS-sparing protocols combining calcineurin inhibitors (CNI) and mycophenolate or sirolimus, have been mixed for rejection and survival rates. Most of the studies were uncontrolled trials of low-risk patients, therefore the grade of evidence is limited. Large-scale prospective studies with long-term follow up are necessary to assess risks and benefits of CS-sparing regimens in PT before recommending such strategies as standard practice. Islet allo-transplantation for patients with brittle type 1 diabetes mellitus, less invasive and safer procedure than PT, has been attempted since late 1980s, but diabetogenic immunosuppressants at maintenance, mainly CS and high-dose CNI, prevented satisfactory results (10% insulin-independence at 1-year post-transplant). Since 2000, CS-free and CNI-reducing protocols, including more potent induction [daclizumab, OKT3γ1(ala-ala) anti-CD3 antibody, rATG] and maintenance (sirolimus, mycophenolate) agents, have significantly improved short-term outcomes whereas long-term are still inadequate (from 80% to 20% insulin-independence from 1- to 5-year post-transplant). Main limitations are allo- and autoimmunity, immunosuppression-related islet and systemic toxicity and transplant site unsuitability, which tolerogenic protocols and biotechnological solutions may solve.

KW - Gluco-corticosteroids

KW - Immunosuppression

KW - Islet transplantation

KW - Pancreas transplantation

KW - Side-effects

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=57349148359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349148359&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2008.00761.x

DO - 10.1111/j.1432-2277.2008.00761.x

M3 - Review article

C2 - 18855850

AN - SCOPUS:57349148359

VL - 22

SP - 20

EP - 37

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 1

ER -